ABSTRACT
We have examined analogs of the previously reported 7-deaza-2'-deoxypurine nucleoside triphosphate series of human telomerase inhibitors. Two new telomerase-inhibiting nucleotides are reported: 6-methoxy-7-deaza-2'-deoxyguanosine 5'-triphosphate (OMDG-TP) and 6-thio-7-deaza-2'-deoxyguanosine 5'-triphosphate (TDG-TP). In particular, TDG-TP is a very potent inhibitor of human telomerase with an IC(50) of 60 nM. TDG-TP can substitute for dGTP as a substrate for telomerase, but only at relatively high concentrations. Under conditions in which TDG-TP is the only available guanosine substrate, telomerase becomes nonprocessive, synthesizing short products that appear to contain only one to three TDG residues. Similarly, the less potent telomerase inhibitor OMDG-TP gives rise to short telomerase products, but less efficiently than TDG-TP. We show here that TDG-TP, and to a lesser extent OMDG-TP, can serve as substrates for both templated (Klenow exo) and nontemplated (terminal transferase) DNA polymerases. For either polymerase, the products arising from TDG-TP are relatively short, and give rise to bands of unusual mobility under PAGE conditions. These anomalous bands revert, under treatment with DTT, to normal mobility bands, indicating that these products may contain thiol-labile disulfide linkages involving the incorporated TDG residues. This observation of potential TDG-crosslinks may have bearing on the mechanism of telomerase inhibition by this nucleotide analog.
Subject(s)
Deoxyguanine Nucleotides/chemical synthesis , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Telomerase/antagonists & inhibitors , DNA Polymerase I/antagonists & inhibitors , Deoxyguanine Nucleotides/pharmacology , Humans , In Situ Nick-End Labeling , Structure-Activity RelationshipABSTRACT
Acrolein is a highly electrophilic alpha,beta-unsaturated aldehyde to which humans are exposed in various situations. Acrolein reacts rapidly with and depletes cellular glutathione (GSH), and is toxic to various types of cells. In the current study, the ability of acrolein to alter proliferation of A549 cells was found to be dependent on cell density as well as total cell number. Thus, 'doses' must be expressed per cell rather than as a concentration, and all related studies need to be performed by plating a constant number of cells. A549 cells were plated at various densities and treated with acrolein after 48 h. Acrolein doses up to 47 fmol/cell at the time of treatment did not cause cell lethality. However, growth of A549 cells (as shown by thymidine incorporation, alamarBlue and total protein) was inhibited at acrolein levels > 34 fmol/cell in 6-well plates seeded at 5000 cells/cm2 48 h prior to treatment. Cellular GSH levels were decreased 34% by 2 h at acrolein levels of 6.7 fmol/cell and by 65% at 47 fmol/cell. Recovery of GSH was rapid at 6.7-47 fmol/cell acrolein, returning to control levels or above by 12 h post-treatment. These data show a strong correlation between cellular GSH and proliferation. The apparent conflict with a previous study of Ramu et al., suggesting that sublethal concentrations (up to 10 microM) of acrolein inhibited the proliferation of A549 cells without a decline in total cellular GSH, arose because, while the acrolein concentration was the same in cells used for proliferation and GSH assays, GSH measurements were done in cells plated at a higher density, resulting in a much lower acrolein dose per cell. Interestingly, very low dose levels of acrolein with cells seeded at low densities stimulated cell growth despite an initial decline in GSH content. Preliminary studies with the stress genes hsp70 and gadd153 suggest that acrolein at 35 fmol/cell does not stimulate formation of their mRNA beyond the level stimulated by a 2 h incubation in serum-free medium but may actually delay or decrease the induced expression. The mechanism(s) of the inhibitory and mitogenic effects of acrolein remains to be determined, but could be due to changes in gene expression induced by this electrophile, perhaps mediated by changes in GSH.
Subject(s)
Acrolein/toxicity , Adenocarcinoma/pathology , CCAAT-Enhancer-Binding Proteins , Glutathione/drug effects , Lung Neoplasms/pathology , Adenocarcinoma/metabolism , Cell Count/drug effects , Cell Division/drug effects , Cell Survival/drug effects , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/drug effects , Growth Inhibitors/toxicity , HSP70 Heat-Shock Proteins/biosynthesis , HSP70 Heat-Shock Proteins/drug effects , Humans , Lung Neoplasms/metabolism , Nuclear Proteins/biosynthesis , Nuclear Proteins/drug effects , Transcription Factor CHOP , Transcription Factors/biosynthesis , Transcription Factors/drug effects , Tumor Cells, CulturedABSTRACT
Two nonprotein amino acids, cycasindene and cycasthioamide, along with eight known nonprotein amino acids, were isolated from the seeds of Cycas revoluta Thunb. The structures of cycasindene and cycasthioamide were elucidated as 3-[3'-amino-indenyl-2]-alanine (1) and N-[glycinyl-alaninyl-11-thio]-5-one-pipecolic acid (2) by chemical and spectral methods.
Subject(s)
Alanine/analogs & derivatives , Pipecolic Acids/chemistry , Pipecolic Acids/isolation & purification , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Plants/chemistry , Alanine/chemistry , Alanine/isolation & purification , Magnetic Resonance Spectroscopy , Seeds/chemistryABSTRACT
Bacillomycin Lc, a new antifungal antibiotic of the iturin class, was isolated from a strain of Bacillus subtilis as a set of five congeners. The structure as determined by chemical and spectrometric analyses has been shown to differ from that of bacillomycin L by sequence changes from aspartate-1 to asparagine-1 and from glutamine-5 to glutamate-5. The five congeners differ from each other only in the structure of the aliphatic side chain of the constituent beta-amino acid. The hydrophobicity of the beta-amino acid affects the antifungal activity of the congener, as activity increased in the order of increased congener retention on a reversed-phase HPLC column.
